<DOC>
	<DOCNO>NCT01522794</DOCNO>
	<brief_summary>The purpose study assess effect anti-hepcidin Spiegelmer NOX-H94 iron homeostasis systemic inflammation induce endotoxin . In human endotoxemia model , intravenously administer lipopolysaccharide elicits inflammatory response release pro-inflammatory cytokine , IL-6 TNF-alfa , subsequent induction hepcidin . As consequence hepcidin induction , serum iron concentration decrease . This study healthy subject investigate capacity NOX-H94 inactivate hepcidin prevent serum iron decrease pathophysiological model prior study efficacy NOX-H94 patient anemia chronic disease .</brief_summary>
	<brief_title>Pharmacokinetics/Pharmacodynamics NOX-H94 Human Endotoxemia Model</brief_title>
	<detailed_description />
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Endotoxemia</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<criteria>Main BMI 18 30 kg/m² , low limit body weight 50 kg Healthy determine medical history , physical examination , vital sign , 12 lead electrocardiogram , clinical laboratory parameter Serum iron red blood parameter Hb , MCV , ferritin , serum iron , total iron binding capacity within reference range Main Use medication , recreational drug antioxidant vitamin supplement within 7 day Use caffeine , nicotine , alcohol within 1 day Previous participation trial LPS administer Surgery trauma significant blood loss blood donation within 3 month History , sign symptoms cardiovascular disease ( vasovagal collapse orthostatic hypotension , Resting pulse rate ≤45 ≥100/min , Hypertension , Hypotension , ECG conduction abnormality ) Renal impairment : plasma creatinine &gt; 120 µmol/L Liver function test ( alkaline phosphatase , AST , ALT γGT ) outside reference range total bilirubin &gt; 20 µmol/L Hemoglobin iron parameter ( iron , transfer saturation , ferritin ) outside reference range History asthma Immunodeficiency Positive test HIV type 1/2 antibody , HBs antigen , HBc antibodies HCV antibody unless antibody titer induce vaccination CRP &gt; reference range clinically significant acute illness , include infection , within 2 week Treatment investigational drug participation clinical trial within 30 day prior study drug administration Known suspect able comply trial protocol Inability personally provide write informed consent and/or take part study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>